MS Pharma, the fast growing Jordanian based pharmaceutical company operating across the MENA region, today announces a $50 million equity investment from the European Bank for Reconstruction and Development (EBRD).
The investment will be used to acquire a generics manufacturing plant in Turkey and accelerate the group’s expansion into the Turkish pharmaceutical market. The investment will also enable the group to increase its capacity at its production sites in Jordan, diversify its revenue streams and accelerate entry into new markets.
Ghiath Sukhtian, MS Pharma Chairman, said:
“We are delighted that EBRD has invested in MS Pharma, thereby recognising our financial strength, high standards of corporate governance and growth potential. This investment will make a significant contribution to our emerging pharmaceutical platform in the region and our expanding international footprint”
Frederic Lucenet, EBRD Director for Manufacturing and Services, added:
“We are very pleased to support MS Pharma, a key player in pharmaceuticals in the Middle East and North Africa. The pharmaceutical industry has witnessed considerable growth over the last year, as the population is growing and the demands for higher healthcare standards are increasing. We will fully support MS Pharma to further grow its operations on the basis of its strong potential.’’